it stops whole mycolic acid biosynthesis

lenalidomide, a chemotherapeutic agent FDA approved for the treatment of multiple myeloma, is shown to have several immunomodulatory effects, including stimulation of NK cell cytotoxicity, enhancement Crizotinib of T cell function, and suppression of proliferation and Treg function. 77, 78 Like other agents of its course, lenalidomide is also antiangiogenic and anti-apoptotic, and can decrease the metastatic capacity of tumors. 79, 80 There's increasing interest in the possible therapeutic benefits of regimens combining cancer vaccines plus standard of care chemotherapy. However, there are numerous important considerations. First, utilizing vaccine and chemotherapy early in the disease process may have somewhat different clinical results than administering vaccine after numerous chemotherapeutic regimens in advanced stage disease, once the immune system is almost certainly impaired. Minute, not all chemotherapeutic agents are appropriate for vaccine. And third, when combined with chemotherapy, the time of vaccine administration may be extremely important. Acquiring pre-clinical evidence of the immunomodulatory effects of chemotherapy gifts Metastasis new alternatives for combining chemotherapy with vaccine to generate effective antitumor immunity in the clinical setting. A few mature programs already are being used clinically. Further clinical studies is likely to be needed to improve the use of these and other combination regimens. In the last decade, utilization of targeted SMIs for that treatment of numerous tumor types has increased. 81 The main difference between standard chemotherapeutic agents and SMIs is the fact that the previous reduce rapidly growing cells whilst the latter target specific Imatinib proteinprotein interactions, including growth facets and their receptors. 82 In comparison to standard chemotherapy, specific therapy with SMIs gets the benefit of modulating specific cellular pathways that are critical for cyst biology, along with the advantages of increased effectiveness and decreased toxicity. Additionally there are many potential benefits of combining SMIs with immunotherapy. Immune activation can be selectively increased by some SMIs by inhibiting immune suppressor cells such as Tregs and MDSCs and/or by causing immune effector cells such as CTLs and DCs. SMIs will make tumor cells more susceptible to immune mediated killing by improving tumor distinct antigen presentation and/or FAS mediated killing. Also, the synergistic effect of mixing SMIs with vaccine can justify the government of SMIs at a lower dose, further decreasing the possibility of accumulation. Achieving an optimal result when combining immunotherapy and SMIs involves determining the correct timing of SMI treatment and vaccine administration. The most effective combination routine must lead to robust immune arousal against TAAs, with little if any toxicity against immune effector cells.